6-benzyloxychroman-4-one | 123094-61-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-benzyloxychroman-4-one
• 英文别名: 6-benzyloxy-4-chromanone；6-phenylmethoxy-2,3-dihydrochromen-4-one
• CAS: 123094-61-1
• 化学式: C₁₆H₁₄O₃
• 分子量: 254.285
• InChiKey: TXHCNZIDIHQNBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-benzyloxychroman-4-one 在 palladium dihydroxide 、 palladium on activated charcoal 四氢吡咯 、 4-二甲氨基吡啶 、 sodium hydroxide 、 sodium tetrahydroborate 、 cerium(III) chloride 、 乙胺嗪 、 TEA 、 二苯基磷酸 、 氢气 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 (3R,4R)-3-[(5-amino-2-methoxyphenyl)methyl]-3,4-dihydro-2H-chromene-4,6-diol
  参考文献：
  名称：

  Discovery of CP-199,330 and CP-199,331: Two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity

  摘要：

  CP-199,330 (3) and CP-199,331 (4) are cysLT(1) receptor antagonists that are equipotent to marketed cysLT(1) receptor antagonists zafirlukast and pranlukast, show good pharmacokinetics in rats and monkeys, and are devoid of liver toxicity in monkeys as seen in CP-85,958 (1). (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00461-8
• 作为产物：
  描述：

  6-甲氧基-4-二氢色原酮 在 氢溴酸 、 potassium carbonate 、 溶剂黄146 作用下， 以 丙酮 为溶剂， 生成 6-benzyloxychroman-4-one
  参考文献：
  名称：

  Discovery of CP-199,330 and CP-199,331: Two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity

  摘要：

  CP-199,330 (3) and CP-199,331 (4) are cysLT(1) receptor antagonists that are equipotent to marketed cysLT(1) receptor antagonists zafirlukast and pranlukast, show good pharmacokinetics in rats and monkeys, and are devoid of liver toxicity in monkeys as seen in CP-85,958 (1). (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00461-8

文献信息

• Synthesis of Flavanones via Palladium(II)-Catalyzed One-Pot β-Arylation of Chromanones with Arylboronic Acids
  作者：Hyung-Seok Yoo、Seung Hwan Son、Yang Yil Cho、Soo Jin Lee、Hyu Jeong Jang、Young Min Kim、Dong Hwan Kim、Nam Yong Kim、Boyoung Y. Park、Yong Sup Lee、Nam-Jung Kim

  DOI：10.1021/acs.joc.9b01162

  日期：2019.8.16

  total of 47 flavanones were expediently synthesized via one-pot β-arylation of chromanones, a class of simple ketones possessing chemically unactivated β sites, with arylboronic acids via tandem palladium(II) catalysis. This reaction provides a novel route to various flavanones, including natural products such as naringenin trimethyl ether, in yields up to 92%.

  合宜地通过一锅二价的苯并二氢吡喃酮与芳基硼酸通过串联钯（II）催化合成了苯并二氢吡喃酮（一类具有化学未活化β位点的简单酮），合成了47种黄烷酮。该反应提供了一种以高达92％的收率获得各种黄烷酮（包括天然产物，如柚皮苷三甲醚）的新颖途径。
• Substituted tetralins, chromans and related compounds in the treatment
  申请人：Pfizer Inc.

  公开号：US05059609A1

  公开（公告）日：1991-10-22

  Substituted tetralins, chromans and related compounds which, by inhibiting 5-lipoxygenase enzyme and/or blocking leukotriene receptors, are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction and related disease states in mammals, pharmaceutical compositions thereof, a method of treatment therewith, and to intermediates useful in the synthesis thereof.

  取代四氢萘、环己烷和相关化合物，通过抑制5-脂氧酶酶和/或阻断白三烯受体，在哺乳动物中可用于预防或治疗哮喘、关节炎、牛皮癣、溃疡、心肌梗死及相关疾病状态的药物组合物，以及用于治疗的方法，以及用于合成的中间体。
• Substituted chromans and their use in the treatment of asthma, arthritis
  申请人：Pfizer Inc.

  公开号：US05298512A1

  公开（公告）日：1994-03-29

  Substituted chromans which by inhibiting 5-lipoxygenase enzyme are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction, stroke and related disease states in mammals, pharmaceutical compositions thereof, a method of treatment therewith, and to intermediates useful in the synthesis thereof.

  通过抑制5-脂氧酶酶而被替代的色甚醚类化合物在哺乳动物中预防或治疗哮喘、关节炎、牛皮癣、溃疡、心肌梗死、中风及相关疾病状态中具有用处，其中包括药物组合物、治疗方法以及用于合成的中间体。
• Sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl
  申请人：Pfizer Inc.

  公开号：US05641789A1

  公开（公告）日：1997-06-24

  Compounds of the formula ##STR1## and pharmaceutically acceptable salts and prodrugs thereof, wherein X.sup.1, Ar, X, Y.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.5 and n are defined below, which are inhibitors of the production of leukotrienes and/or blockers of leukotriene receptors, methods for preparing said compounds and intermediates useful in the preparation thereof, pharmaceutical compositions thereof methods of treatment therewith. The compounds of the above formula are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction and related diseases in mammals.

  该公式化合物##STR1##及其药学上可接受的盐和前药，其中X.sup.1、Ar、X、Y.sup.1、R.sup.1、R.sup.2、R.sup.3、R.sup.5和n的定义如下，它们是白三烯产生的抑制剂和/或白三烯受体的阻断剂，制备这些化合物的方法及制备中有用的中间体，这些化合物的药物组成物及治疗方法。上述公式的化合物在哺乳动物中预防或治疗哮喘、关节炎、牛皮癣、溃疡、心肌梗死及相关疾病中是有用的。
• Quinoline-substituted chromans and related compounds as leukotriene
  申请人：Merck Frosst Canada, Inc.

  公开号：US05149703A1

  公开（公告）日：1992-09-22

  Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

  化学式为I的化合物：##STR1## 是白三烯作用的拮抗剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。它们还可用于治疗心绞痛、脑痉挛、肾小球肾炎、肝炎、内毒素血症、葡萄膜炎和移植排斥反应。